What is Dianthus Therapeutics's AOCI?

Dianthus Therapeutics (DNTH) reported AOCI of -$575K in Q1 2026.

How has Dianthus Therapeutics's AOCI changed year-over-year?

Dianthus Therapeutics's AOCI decreased by 313.0% year-over-year, from $270K to -$575K.

What is the long-term trend for Dianthus Therapeutics's AOCI?

Over 5 years (2020 to 2025), Dianthus Therapeutics's AOCI has grown at a 84.3% compound annual growth rate (CAGR), from -$23K to $489K.

Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.

Dianthus Therapeutics DNTH AOCI

AOCI at other companies

Johnson & JohnsonJNJ

-$14.83B-26.3%

AmgenAMGN

-$190M+17.7%

Spyre Therapeutics, Inc.SYRE

-$767K-212%

Kymera TherapeuticsKYMR

-$4.19M-7,131%

Protagonist TherapeuticsPTGX

-$269K-416%

Immunovant, Inc.IMVT

$730K-50.0%

Other financials

Income statement

See full

Revenue$396.0K-81.8%

Operating income-$46.5M-40.3%

Net income-$40.8M-38.4%

EPS (diluted)-$0.85-3.7%

Balance sheet

See full

Cash & equivalents$627.7M+6,105%

Total debt$1.4M-2.3%

Total equity$1.2B+266%

Total assets$1.2B+258%

Cash flow

See full

Operating cash flow-$28.9M-4.4%

CapEx$10.0K-58.3%

Free cash flow-$28.9M-4.4%

Valuation

See full

Market cap$4.51B+662%

Profitability

See full

Operating margin-4,558.4%-9,354pp

Net margin-4,104.8%-7,304pp

FCF margin-3,561.6%-6,956pp

Returns & leverage

See full

Return on equity-28.6%+3.2pp

Debt / equity0×0.0×

Current ratio29.3×+13.3×

Where this comes from

Reported directly by Dianthus Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.

The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dianthus Therapeutics's aoci.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Dianthus Therapeutics's AOCI?: Dianthus Therapeutics (DNTH) reported AOCI of -$575K in Q1 2026.
How has Dianthus Therapeutics's AOCI changed year-over-year?: Dianthus Therapeutics's AOCI decreased by 313.0% year-over-year, from $270K to -$575K.
What is the long-term trend for Dianthus Therapeutics's AOCI?: Over 5 years (2020 to 2025), Dianthus Therapeutics's AOCI has grown at a 84.3% compound annual growth rate (CAGR), from -$23K to $489K.
What does AOCI mean?: Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.